Teppei Yamada Selected Research

Teppei Yamada Research Topics

Disease

13	Neoplasms (Cancer) 01/2023 - 01/2013
12	Colorectal Neoplasms (Colorectal Cancer) 03/2024 - 06/2015
3	Adenocarcinoma 01/2021 - 06/2017
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2017 - 10/2014
2	Fistula 04/2024 - 01/2017
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2019 - 01/2015
2	Pain (Aches) 12/2019 - 01/2016
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 04/2024
1	Rectal Neoplasms (Rectal Cancer) 03/2024
1	Stomach Neoplasms (Stomach Cancer) 01/2023
1	Joint Diseases (Joint Disease) 12/2021
1	Sigmoid Neoplasms 02/2021
1	Thrombosis (Thrombus) 02/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 02/2021
1	Margins of Excision 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Inflammation (Inflammations) 10/2020
1	Melanoma (Melanoma, Malignant) 08/2019
1	Photosensitivity Disorders (Photodermatitis) 04/2019
1	Acute Kidney Injury (Acute Renal Failure) 10/2018
1	Esophageal Squamous Cell Carcinoma 08/2018
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2017
1	Esophageal Neoplasms (Esophageal Cancer) 01/2017
1	Anastomotic Leak 01/2017
1	Acute Cholecystitis 12/2015
1	Dihydropyrimidine Dehydrogenase Deficiency 09/2015
1	Neutropenia 06/2015
1	Lung Neoplasms (Lung Cancer) 01/2013

Drug/Important Bio-Agent (IBA)

8	Peptides (Polypeptides)IBA 02/2021 - 10/2014
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 01/2015
2	folfirinoxIBA 01/2021 - 12/2019
2	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 01/2020
2	Histocompatibility Antigens Class IIBA 08/2019 - 01/2018
2	Protein Subunit VaccinesIBA 04/2017 - 10/2015
1	Phenobarbital (Luminal)FDA Link 04/2024
1	ParaffinIBA 01/2023
1	Trastuzumab (Herceptin)FDA Link 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	Formaldehyde (Formol)FDA Link 01/2023
1	Circulating Tumor DNAIBA 01/2022
1	Histone Deacetylase InhibitorsIBA 01/2021
1	Leucovorin (Folinic Acid)FDA Link 01/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 10/2020
1	InflammasomesIBA 10/2020
1	5-nitrouracilIBA 01/2020
1	Capecitabine (Xeloda)FDA Link 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 12/2019
1	EnzymesIBA 08/2019
1	Monoclonal AntibodiesIBA 08/2019
1	HLA-B Antigens (HLA-B)IBA 08/2019
1	PorphyrinsIBA 04/2019
1	Coloring Agents (Dyes)IBA 04/2019
1	HLA-A Antigens (HLA-A)IBA 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 10/2018
1	Folate Receptor 1IBA 06/2017
1	HaptoglobinsIBA 02/2017
1	Asu(1,6)- argipressin (VAS-A)IBA 01/2016
1	EpitopesIBA 10/2015
1	Immunoglobulin G (IgG)IBA 10/2015
1	HLA-A*26 antigenIBA 10/2015
1	Bevacizumab (Avastin)FDA Link 06/2015
1	XELOXIBA 06/2015
1	ErbB Receptors (EGF Receptor)IBA 01/2013
1	Tyrosine Kinase InhibitorsIBA 01/2013
1	AntigensIBA 01/2013
1	Gefitinib (Iressa)FDA Link 01/2013
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2013

Therapy/Procedure

9	Drug Therapy (Chemotherapy) 03/2024 - 06/2015
6	Therapeutics 03/2024 - 06/2015
2	Cell- and Tissue-Based Therapy (Cell Therapy) 03/2024 - 08/2020
2	Perioperative Period 01/2022 - 01/2021
2	Esophagectomy 08/2018 - 01/2017
1	Ligation 04/2024
1	Immunotherapy 03/2024
1	Catheters 02/2021
1	Adjuvant Chemotherapy 02/2021
1	Neoadjuvant Therapy 01/2021
1	Hepatectomy 01/2021
1	Islets of Langerhans Transplantation 10/2020
1	Combination Drug Therapy (Combination Chemotherapy) 12/2019
1	Intravenous Infusions 01/2016
1	Laparoscopic Cholecystectomy 12/2015
1	Cholecystectomy 12/2015
1	Conversion to Open Surgery 12/2015